信迪利单抗联合化疗对晚期肺癌患者T细胞亚群及疾病缓解情况与不良反应的影响  

Effect of cindilizumab combined with chemotherapy on T cell subsets,disease remission and adverse reactions in patients with advanced lung cancer

作　　者：李洁 吴文峰 陈卫琴 LI Jie;WU Wenfeng;CHEN Weiqin(Department of Respiratory and Critical Care Medicine,Fuzhou First People's Hospital,Fuzhou,Jiangxi,344100,China)

机构地区：[1]抚州市第一人民医院呼吸与危重症医学科,江西抚州344100

出　　处：《当代医学》2025年第1期57-61,共5页Contemporary Medicine

摘　　要：目的探究信迪利单抗联合化疗对晚期肺癌患者T细胞亚群及疾病缓解情况、不良反应的影响。方法选取2022年1月至2023年6月抚州市第一人民医院收治的80例晚期肺癌患者作为研究对象,采用随机数字表法分为A组与B组,各40例。A组接受吉西他滨联合顺铂(GP方案)化疗,B组在A组基础上联合应用信迪利单抗治疗,比较两组临床疗效、T细胞亚群水平、血清肿瘤标志物水平、不良反应发生情况。结果两组客观缓解率比较差异无统计学意义;B组疾病控制率为65.00%,高于A组的42.50%,差异有统计学意义(P<0.05)。治疗后,A组CD4^(+)水平及CD4^(+)/CD8^(+)均低于治疗前,B组CD3+、CD4^(+)、CD8^(+)水平及CD4^(+)/CD8^(+)均高于治疗前,且B组CD3+、CD4^(+)水平及CD4^(+)/CD8^(+)均高于A组,CD8^(+)水平低于A组,差异有统计学意义(P<0.05)。治疗后,两组血清铁蛋白、癌胚抗原、鳞状细胞癌抗原、神经元特异性烯醇化酶、细胞角蛋白19片段抗原21-1、糖类抗原125水平均低于治疗前,且B组低于A组,差异有统计学意义(P<0.05)。两组恶心呕吐、骨髓抑制、肾脏毒性比较差异无统计学意义。结论信迪利单抗联合化疗治疗晚期肺癌患者效果确切,可改善患者血清肿瘤标志物水平及T细胞亚群水平,且未增加不良反应发生。Objective To explore the effect of cindilizumab combined with chemotherapy on T cell subsets,disease remission and adverse reactions in patients with advanced lung cancer.Methods A total of 80 patients with advanced lung cancer admitted to Fuzhou First People's Hospital from January 2022 to June 2023 were selected as the study subjects,and they were divided into the group A and the group B by random number table method,with 40 cases in each group.The group A received gemcitabine combined with cisplatin(GP regimen)chemotherapy,the group B was combined with sindellizumab on the basis of the group A,and the clinical efficacy,T cell subsets,serum tumor marker levels and the occurrence of adverse reactions were compared between the two groups.Results There was no significant difference in objective remission rate between the two groups.The disease control rate in the group B was 65.00%,which was higher than 42.50%in the group A,and the difference was statistically significant(P<0.05).After treatment,the of CD4^(+)level and CD4^(+)/CD8^(+)in the group A were lower than before treatment,the CD3+,CD4^(+),CD8^(+)levels and CD4^(+)/CD8^(+)in the group B were higher than before treatment,and the CD3+,CD4^(+)levels and CD4^(+)/CD8^(+)in the group B were higher than those in the group A,and the level of CD8^(+)was lower than that in the group A,and the differences were statistically significant(P<0.05).After treatment,the levels of serum ferritin,carcino embryonic antigen,squamous cell carcinoma antigen,neuron-specific enolase,cyto-keratin 19 fragment antigen 21-1 and carbohydrate antigen 125 of the two groups were lower than before treatment,and the group B was lower than the group A,and the differences were statistically significant(P<0.05).There was no significant difference in nausea,vomiting,bone marrow suppression and nephrdoxicity between the two groups.Conclusion Cindilizumab combined with chemotherapy can improve the therapeutic effect,improve the level of serum tumor markers and T cell subsets in patients with advan

关 键 词：晚期肺癌 信迪利单抗 T细胞亚群 

分 类 号：R734.2[医药卫生—肿瘤]